CHEK1 and small cell lung carcinoma: Mechanistically, other cell-cycle or DDR inhibitors (targeting PARP, CHK1, or CDK7) in SCLC elicited antitumor responses through immune reengagement and direct antitumor effects (Sen et al., 2019a, 2019b; Zhang et al., 2020).